calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review GLP-1 Receptor Agonists as Treatments
Description
Growth is supported by urbanization, public health initiatives targeting metabolic diseases, and growing demand for effective, long-term weight loss solutions in both primary and specialist care settings

D., Brand, C

[DOI] [PubMed] [Google Scholar] 11.Cuttica CM, Briata IM, DeCensi A

BMJ 2023;382:p2019.Article 72

In addition, SGLT-2is contribute to better cardiovascular outcomes by stimulating erythropoiesis (leading to improved oxygenation of ischemic tissues), reducing proinflammatory adipokines, and reducing cardiac necrosis [16, 53,54,55,56]

Payer Action Plan Monitor the Drug Pipeline: At this time, there is no action that payers need to take
